ImetelChat

Hello all, (or at least the few hard core believers, or I like to think smart + patient ones) Respectfully I have a different opinion of this idea of activist role. I say stay the course, and no need to disrupt. - 10 years ago the discovery of the enzyme Telomerase was published, and received the No...

Having key institutions worldwide already involved in the trials, with their clinicians trained, will help facilitate this uptake. This is the kind of problem I would be extremely happy with, and most likely quite a while away.* *Although provisional approval in the Triple Negative cohort should be ...

I'd say these are aggressive prognostications albeit reachable in theory. Approval for TN (Triple-Negative) patients in MF should happen now if not sooner. The key to you post is the parenthetical about Janssen's 'clerical error'. This would be an error by perhaps a half-dozen or more trained profes...

I would never question your right to question management, I just wouldn't hold out hope for anything but the canned answers we all have seen. What I would do is refocus on the superior data presented as ASH and the real developments that are happening... Here are some of the developments that have h...

Indeed, I have been tempted to speculate... but why not just wait to see the reveal... now just about 6 hours away...

Let's talk then

Of course this post doesn't dignify a response, however I see almost 400 views on this thread so I'll jump in: Geron exists. It appears Nobel Prize winning theory is translating to "groundbreaking results" (5 years ago, as stated in the Mayo Clinic brochure, "tantamount to a cure in some cases") for...

Basically agreeing - Seems everything is pointing in the right direction except the timeline. Which is admittedly brutal. I don't think there is much to try to interpret about Dr. Raza, cause we'll hear from her in a couple weeks. As well as Dr. Steensma, who surprisingly disagreed with Dr. Raza's D...

I am as confounded as most, by the study design and the slow path to regulatory review, for a therapy that appears to be transformational.

The answers to your specific questions are most likely only known to corporate insiders, and anyone they may have discussed it with.

Here are some of my musings, summing up the recent history of Imetelstat/Geron... it got buried on the Y! board with more than a dozen thumb-downs. I mention that cause the post also is in relation to the stock price, which is a little out-of-bounds for this board, imo. Hopefully we're through the s...

Smiley faces added :lol: (Staying positive) (Editor removals ~~Your message contains too many smilies. The maximum number of smilies allowed is 1.~~ God Bless Fish, he ran a tight ship,,, I replaced with Astericks, smiley face emoticon with exclamation point!) https://www.vjhemonc.com/video/g7alpq7r...

Hello Kara, It appears you are missing something. The data was not mediocre. Have you ever sat in a room where a loved one was told by a doctor that the current therapy is no longer effective, and there are no options left but to minimize pain? In these blood cancers, physicians also find it very di...

I have to add ~ the Compassionate Use for Imetelstat *was* online. I saw it, it was an official site, and it was there. Then it was down. Follow me here ~ for Imet to wind up available for Compassionate Use, even for a micro-second, it would have to pass through Doctors / Experts / Clinicians involv...

Totally understand - take some time and enjoy some fresh autumn air. My point on ASH is if this clinical data is not strong, we won't see it at ASH. If either of these abstracts are accepted by ASH, then there is developments of merit in these trials. And I just don't believe Janssen would even subm...

Hello BP, I feel inclined to reply to your post, and the reply, in support. And dovetail on a point you made.... (ps - it's towards the end and ends with Period.) I'll refrain from 'forward looking + statements', however I am compelled to agree with your points. You are correct that these trials are...

Yes, finally after all these years, this could be the week we have a(n initial culmination). And if not this week, only a week or two more. So in the sands of time of Geron, this is a heartbeat away. And if all goes as expected, with a Continuation from Janssen followed by an opt-in from GERN, the n...

No cards shown - although I think he is tipping his hand with the second 'derisk' statement and confidence in either decision from Janssen.

(the Decision is yes.)

I agree with all the points. It is a foregone conclusion that Janssen will Continue and Geron now has the funds to confidently opt-in - ET which showed near 100% remission - Mayo Pilot studies as peer reviewed in NEJM, 'tantamount to a cure' in some cases as stated in Mayo Clinic brochures - MF tria...

Hello again, I believe this filing is identical (up to $250 M) as the one last month except they amended to include (or grant shares or something) to the investment firm handling the potential sale. So I could be wrong but I don't think this is anything new but an amendment to what we have seen. How...

Thank you, Biopearl, for posting and maintaining the site. This is a fantastic pre-clinical. I'm playing in my head to try to decide which pre-clinical has bigger implications, the AML combo published at ASH 2016 or this one. I'm thinking AML combo has more immediate impact, however in the long (and...

My sincere condolences.

His passion was clear, and he never let on to his personal battles.

A very sad day, and I wish Imet therapy could have come to fruition for him to see...